Biogen bites back at critics of Aduhelm after drug’s slow startBiogen has reported $2m in sales for newly-launched Alzheimer’s therapy Aduhelm that came in below its expectations, prompting Share XBiogen bites back at critics of Aduhelm after drug’s slow starthttps://pharmaphorum.com/news/biogen-bites-back-at-critics-of-aduhelm-after-drugs-slow-start/
Ogilvy Health promotes Rebecca Carter to Head of Social MediaOgilvy Health UK has promoted Rebecca Carter to the newly created role of Head of Social Media. Carter Share XOgilvy Health promotes Rebecca Carter to Head of Social Mediahttps://pharmaphorum.com/sales-marketing/ogilvy-health-promotes-rebecca-carter-to-head-of-social-media/
Is J&J nearing the end of its opioid liability hangover?Johnson & Johnson and the ‘big three’ US pharma wholesalers are on the brink of a $26 billion Share XIs J&J nearing the end of its opioid liability hangover?https://pharmaphorum.com/news/is-jj-nearing-the-end-of-its-opioid-liability-hangover/
UK comms agency Fishawack Health restructures creative teamFishawack Health has announced a restructuring of its creative team to expand client support across global markets. The Share XUK comms agency Fishawack Health restructures creative teamhttps://pharmaphorum.com/news/fishawack-health-restructures-creative-team/
Healthware Group appoints Giovanni Loria as chief financial officerGiovanni Loria has joined global digital health innovation organisation Healthware Group as its new chief financial officer. He Share XHealthware Group appoints Giovanni Loria as chief financial officerhttps://pharmaphorum.com/news/healthware-group-appoints-giovanni-loria-as-chief-financial-officer/
UK fines drugmakers record £260m for price gouging NHSThe UK’s competition authority has issued its largest ever fine of more than £260 million ($360 million) to Share XUK fines drugmakers record £260m for price gouging NHShttps://pharmaphorum.com/news/uk-fines-drugmakers-record-260m-for-price-gouging-nhs/
Final hurdle falls as UK backs AZ’s $39bn takeover of AlexionThe UK’s competition regulator has approved AstraZeneca’s $39 billion acquisition of US-based drugmaker Alexion, without opting for a Share XFinal hurdle falls as UK backs AZ’s $39bn takeover of Alexionhttps://pharmaphorum.com/news/final-hurdle-falls-as-uk-backs-azs-39bn-takeover-of-alexion/
Performance.io appoints Jason Brown as global chief commercial officerUK-based online marketing agency Performance.io (PIO) has appointed Jason Brown as its global chief commercial officer. Brown has Share XPerformance.io appoints Jason Brown as global chief commercial officerhttps://pharmaphorum.com/news/performance-io/
Big tobacco’s PMI makes another pharma foray with Vectura dealTobacco giant Philip Morris International (PMI) has doubled down on its move into the pharmaceutical sector, following up Share XBig tobacco’s PMI makes another pharma foray with Vectura dealhttps://pharmaphorum.com/news/big-tobaccos-pmi-makes-another-pharma-foray-with-vectura-deal/
Another hurdle down as EU clears AstraZeneca’s Alexion takeoverThe European Commission has given competition clearance to the $39 billion acquisition of Alexion by AstraZeneca, leaving the Share XAnother hurdle down as EU clears AstraZeneca’s Alexion takeoverhttps://pharmaphorum.com/news/another-hurdle-down-as-eu-clears-astrazenecas-alexion-takeover/
Nestle gets closer to Seres, pledging $525m for microbiome C. diff drugSwiss food giant Nestle has firmed up its five-year-old alliance with US microbiome specialist Seres, paying $175 million Share XNestle gets closer to Seres, pledging $525m for microbiome C. diff drughttps://pharmaphorum.com/news/nestle-gets-closer-to-seres-pledging-525m-for-microbiome-c-diff-drug/
Elliott fires broadside at GSK in wake of investor updateGlaxoSmithKline chief executive Emma Walmsley was no doubt hoping that an upbeat assessment of the firm’s prospects at Share XElliott fires broadside at GSK in wake of investor updatehttps://pharmaphorum.com/news/elliott-fires-broadside-at-gsk-in-wake-of-investor-update/
Keytruda beats Opdivo to first-line oesophageal cancer OK in EuropeMerck & Co’s Keytruda has become the first cancer immunotherapy to be approved as a first-line oesophageal cancer Share XKeytruda beats Opdivo to first-line oesophageal cancer OK in Europehttps://pharmaphorum.com/news/keytruda-beats-opdivo-to-first-line-oesophageal-cancer-ok-in-europe/
AZ closes in Forxiga kidney disease label in EU after nod from CHMPAstraZeneca’s fast-growing SGLT2 inhibitor Forxiga could soon get a further boost from approval in the EU as a Share XAZ closes in Forxiga kidney disease label in EU after nod from CHMPhttps://pharmaphorum.com/news/az-closes-in-forxiga-kidney-disease-label-in-eu-after-nod-from-chmp/
Cannes Lions Health awards: 2021 pharma winners announcedThe Cannes Lions Health awards took place this week from 21-25 June, celebrating creativity across industries including pharma. Share XCannes Lions Health awards: 2021 pharma winners announcedhttps://pharmaphorum.com/news/cannes-lions-health-awards-2021-pharma-winners-announced/
McCann Health New York promotes Matt Silver to presidentMcCann Health New York has promoted general manager Matt Silver to the role of president. Silver will lead Share XMcCann Health New York promotes Matt Silver to presidenthttps://pharmaphorum.com/news/mccann-health-new-york-promotes-matt-silver-to-president/
Amid outcry over Aduhelm price, Biogen says it may consider ‘adjustment’Biogen has hinted that it may consider altering the price of its controversially-approved Alzheimer’s therapy Aduhelm – but Share XAmid outcry over Aduhelm price, Biogen says it may consider ‘adjustment’https://pharmaphorum.com/news/amid-outcry-over-aduhelm-price-biogen-says-it-may-consider-adjustment/
Farxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s JardianceAstraZeneca’s SGLT2 inhibitor Farxiga has been growing fast thanks to a first-in-class approval in heart failure, but will Share XFarxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s Jardiancehttps://pharmaphorum.com/news/farxiga-faces-first-heart-failure-rival-as-eu-oks-boehringer-lillys-jardiance/
